Lovenox (enoxaparin sodium) Injection has been approved for use in the prevention of deep vein thrombosis (DVT) which may lead to pulmonary embolism (blood clots in the lung) in patients undergoing abdominal surgery who are at risk for thromboembolic complications.
Surgical patients at risk include those who are over 40 years of age, obese, undergoing surgery with general anesthesia longer than 30 minutes, or who have additional risk factors such as a malignant tumor or a history of deep vein thrombosis or pulmonary embolism.
A new indication for Lovenox was approved in March of 1998. This indication is for the prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction (heart attack) when concurrently administered with aspirin. Unstable angina is a serious condition that can lead to heart attack or death.
Deep vein thrombosis is the formation of blood clots which may lead to pulmonary embolism. Pulmonary embolism occurs when a clot circulates and lodges in the lungs, and can cause sudden death. Venous thromboembolic disease is responsible for more than 400,000 hospitalizations and up to 200,000 deaths each year in the U.S.